← Evidence map

ReviewDrug safety2004

Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.

Alan D Garely et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

4 papers cite it

2004

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

this papercites it

Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. | OpenQuestion